Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13853010 | 0.93 | MAPK14 (0.41) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL13853009 | 0.90 | MAPK14 (0.41) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL4174246 | 0.88 | MAPK13 (0.39) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL4174248 | 0.88 | MAPK13 (0.39) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL4181956 | 0.88 | MAPK14 (0.40) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL4181959 | 0.88 | MAPK14 (0.40) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL10204364 | 0.87 | MAPK14 (0.46) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL13853007 | 0.87 | MAPK14 (0.38) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL5567807 | 0.86 | MAPK13 (0.41) | MAPK14MAPK13MAPK12MAPK11KCNH2 | |
| SCHEMBL6335657 | 0.85 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137550-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-05-28 | — | — | US | disclosed |
| US-20090005401-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-01-01 | — | — | US | disclosed |
| US-7423042-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005401-A1 | Novel Compounds | MAPKAPK2, CREBBP, MAPK8 | MAPK14 53/4885MAPK13 51/4885MAPK12 39/4885 |
| US-20090137550-A1 | Novel Compounds | MAPKAPK2, CREBBP, MAPK8 | MAPK14 53/4885MAPK13 51/4885MAPK12 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.